Meeting Report Europhosphatase 2015: Phosphatases as Drug Targets in Cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27309387.
- Also identified by DOI 10.1158/0008-5472.CAN-15-2091.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Phosphatases are key regulators of cellular signaling and as such play an important role in nearly all cellular processes governing diseases, including cancer. However, due to their highly conserved structure and highly charged and reactive catalytic site, they have been regarded as "undruggable." Fortunately, during the recent Europhosphatase meeting (Turku, Finland), it became clear that phosphatases can no longer be ignored as potential targets in cancer therapy. As reactivation of tumor-suppressor phosphatases or direct inhibition of phosphatases acting as oncogenes is becoming available, this class of enzymes can now be considered as feasible drug targets. Cancer Res; 76(2); 193-6. ©2016 AACR.
Medical subject headings
- Antineoplastic Agents
- Enzyme Inhibitors
- Neoplasms
- Phosphoprotein Phosphatases